Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
British Journal of Haematology
|
June 26, 2018
Daratumumab proves safe and highly effective in AL amyloidosis
Jack Khouri, Andrew Kin, Bicky Thapa, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 1, 2019
Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma
Faiz Anwer, Kevin Mathew Gee, Ahmad Iftikhar, et al.
Blood Cancer Journal
|
January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Vikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
Hematological Oncology
|
February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
Ajai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Transplantation and Cellular Therapy
|
December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Danai Dima, James A Davis, Nausheen Ahmed, et al.
The Lancet. Haematology
|
December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.
Leukemia & Lymphoma
|
April 5, 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Ajai Chari, Sarah Larson, Beata Holkova, et al.
Hematological Oncology
|
June 14, 2024
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, et al.
Blood Cancer Journal
|
April 29, 2026
Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort
Hossam M Ali, Sandra Mazzoni, Utkarsh Goel, et al.
Seminars in Hematology
|
January 29, 2021
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
Jack Khouri, Beth M Faiman, Dale Grabowski, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
British Journal of Haematology
|
June 26, 2018
Daratumumab proves safe and highly effective in AL amyloidosis
Jack Khouri, Andrew Kin, Bicky Thapa, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 1, 2019
Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma
Faiz Anwer, Kevin Mathew Gee, Ahmad Iftikhar, et al.
Blood Cancer Journal
|
January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Vikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
Hematological Oncology
|
February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
Ajai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Transplantation and Cellular Therapy
|
December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Danai Dima, James A Davis, Nausheen Ahmed, et al.
The Lancet. Haematology
|
December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.
Leukemia & Lymphoma
|
April 5, 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Ajai Chari, Sarah Larson, Beata Holkova, et al.
Hematological Oncology
|
June 14, 2024
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy
Danai Dima, Utkarsh Goel, Aishwarya Sannareddy, et al.
Blood Cancer Journal
|
April 29, 2026
Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort
Hossam M Ali, Sandra Mazzoni, Utkarsh Goel, et al.
Seminars in Hematology
|
January 29, 2021
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
Jack Khouri, Beth M Faiman, Dale Grabowski, et al.
Page
of 9